Selection of the right patients for #cancer immunotherapy is challenging. New data on tumor mutational burden predicting survival across a wide variety of cancers: by by #OA
New findings offer latest evidence to suggest that tumours with a large number of DNA mutations are more likely to respond to immunotherapies.
New findings offer latest evidence to suggest that tumours with a large number of DNA mutations are more likely to respond to immunotherapies.
Converging evidence on TMB across different cancers: Highly mutated cancers respond better to immune therapy
Highly mutated cancers respond better to immune therapy
Highly mutated cancers respond better to immune therapy
Interesting and important progress via